News | February 13, 2026
Merck’s KEYTRUDA bags FDA nod for platinum-resistant ovarian cancer
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
Raludotatug deruxtecan is a specifically engineered, potential first-in-class CDH6-directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo
Facility also named 2025 ISPE Facility of the Year Winner for Social Impact - Unmet Medical Needs
The company ensures a reliable and strong portfolio at competitive prices without compromising on excellent quality
Reaffirms Lupin’s commitment to sustainable resource management
Aster CMI Hospital has successfully implemented several key digital health initiatives contributing to this accreditation
PICCOLO trial met its primary endpoint of objective response rate (ORR)
The company's sustainability programme was evaluated on its policies, actions put in place to support objectives and targets, as well as results that were generated from the programme
Sofetabart mipitecan is a novel folate receptor alpha (FR?) antibody-drug conjugate (ADC) leveraging proprietary linker technology and an exatecan payload to target tumor cells
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
Subscribe To Our Newsletter & Stay Updated
